Gerry McKenzie

Corporate Officer/Principal presso AERIE PHARMACEUTICALS, INC.

Health Technology

Profilo

Gerry McKenzie is currently the Vice President-Commercial Operations at Aerie Pharmaceuticals, Inc. He previously worked as the Chief Information Officer at AEON Biopharma Sub, Inc.

Posizioni attive di Gerry McKenzie

Società	Posizione	Inizio
AERIE PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

Tutte le posizioni attive di Gerry McKenzie

Precedenti posizioni note di Gerry McKenzie

Società	Posizione	Fine
AEON Biopharma Sub, Inc. AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.	Chief Tech/Sci/R&D Officer	-

Vedi nel dettaglio l'esperienza di Gerry McKenzie

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Gerry McKenzie

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Aerie Pharmaceuticals, Inc. Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX.	Health Technology
AEON Biopharma Sub, Inc. AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.	Health Technology